<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317899</url>
  </required_header>
  <id_info>
    <org_study_id>17D.404</org_study_id>
    <nct_id>NCT03317899</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Randomized Controlled Trial Evaluating the Use of G-CSF After Plerixafor-Mobilized Autologous Stem Cell Transplant (Auto HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well stem cell transplant with or without tbo-filgrastim&#xD;
      works in treating patients with multiple myeloma or non-Hodgkin lymphoma. Eliminating the use&#xD;
      of tbo-filgrastim after transplant may still help maintain a similar time to discharge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To demonstrate non-inferiority in the number of days to discharge readiness after a&#xD;
      granulocyte colony-stimulating factor (G-CSF) + plerixafor-mobilized autologous stem cell&#xD;
      transplant in patients receiving versus not receiving post-transplant growth factor support.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To compare days to absolute neutrophil count (ANC) &gt; 500, days to platelet engraftment,&#xD;
      febrile days, days of febrile neutropenia, documented infections, and number of antibiotic&#xD;
      days in patients receiving versus not receiving post-transplant growth factor support.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate immunological recovery (lymphocyte number including CD 3/4 and CD3/8 T cell&#xD;
      subsets) at day + 60 in patients receiving versus not receiving post-transplant growth factor&#xD;
      support.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days to discharge</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will compare days to discharge readiness between the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median days post autologous hematopoietic cell transplantation (auto HSCT) to neutrophil engraftment</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be defined as absolute neutrophil count &gt; 500 x 10^9/L x 3 days. Day of engraftment is the first of the 3 days of absolute neutrophil count &gt; 500 x 10^9/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median days post auto HSCT to platelet engraftment</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be defined as date platelet greater than or equal to 20 x 10^9 /L without a platelet transfusion within the last 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of engraftment syndrome</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be defined by the Maiolino Criteria. Will be summarized by treatment arm and compared using a chi-square test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of febrile days during the auto HSCT inpatient stay</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be summarized by treatment arm and compared using Wilcoxon rank sum tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of days of febrile neutropenia during the auto HSCT inpatient stay</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be summarized by treatment arm and compared using Wilcoxon rank sum tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of documented infections treatment during the auto HSCT inpatient stay</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be defined as a positive blood culture not ultimately deemed to be due to a contaminant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of antibiotic days during the auto HSCT inpatient stay</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be summarized by treatment arm and compared using Wilcoxon rank sum tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of days on corticosteroids</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be summarized by treatment arm and compared using Wilcoxon rank sum tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of post discharge granulocyte colony-stimulating factor administrations through day +60 post auto HSCT</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will be summarized by treatment arm and compared using Wilcoxon rank sum tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Group I (auto HSCT tbo-filgrastim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (auto HSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo auto Hematopoietic Cell Transplantation (HSCT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo auto HSCT</description>
    <arm_group_label>Group I (auto HSCT tbo-filgrastim)</arm_group_label>
    <arm_group_label>Group II (auto HSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tbo-filgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Group I (auto HSCT tbo-filgrastim)</arm_group_label>
    <other_name>Filgrastim Biosimilar Tbo-filgrastim</other_name>
    <other_name>Filgrastim XM02</other_name>
    <other_name>Granix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative Studies</description>
    <arm_group_label>Group I (auto HSCT tbo-filgrastim)</arm_group_label>
    <arm_group_label>Group II (auto HSCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing autologous stem cell transplant for one of the following diagnoses:&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Non-Hodgkin lymphoma&#xD;
&#xD;
          -  Karnofsky performance status of &gt;= 70%&#xD;
&#xD;
          -  Patients must meet the Thomas Jefferson University Hospital (TJUH) bone marrow&#xD;
             transplant (BMT) standard of procedure (SOP) guidelines for &quot;Patient Criteria for&#xD;
             Autologous HSCT&quot;&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) of â‰¥ 40%&#xD;
&#xD;
          -  Adjusted Carbon monoxide diffusing capability (DLCO) &gt; 45% of predicted corrected for&#xD;
             hemoglobin&#xD;
&#xD;
          -  Serum bilirubin &lt; 1.8&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 2.5 X upper limit&#xD;
             of normal&#xD;
&#xD;
          -  Serum creatinine =&lt; 2.0 mg/dl and/or creatinine clearance of &gt; 40 ml/min (excludes&#xD;
             multiple myeloma patients receiving high dose melphalan conditioning)&#xD;
&#xD;
          -  Willingness to use contraception if childbearing potential&#xD;
&#xD;
          -  Has the ability to give informed consent, or for cognitively or decisionally impaired&#xD;
             individuals (vulnerable population), the availability of a family member or guardian&#xD;
             to give consent and assist in the consent process&#xD;
&#xD;
          -  Life expectancy of &gt; 12 months (exclusive of the disease for which the auto HSCT is&#xD;
             being performed)&#xD;
&#xD;
          -  Patients must have undergone stem cell mobilization with the combination of G-CSF and&#xD;
             plerixafor as per TJUH BMT SOP guidelines&#xD;
&#xD;
          -  Collection of an adequate number of CD34+ stem cells, i.e. &gt;= 4-6 x 10^6/kg from&#xD;
             apheresis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Uncontrolled bacterial infection&#xD;
&#xD;
          -  Active central nervous system (CNS) disease&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Evidence of another malignancy, exclusive of a skin cancer that requires only local&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolores Grosso, DNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

